While COVID-19 continues to run amok in the United Kingdom, fueled by the new Indian variant. They are facing a new threat: Monkeypox. Two confirmed cases of the extremely communicable West African disease have now been confirmed in the United Kingdom. The world health Organisation said that it was thought to have been introduced in May by a man who had lived and worked in Delta State, Nigeria. The man arrived in the UK and quarantined his family and on May 10, the patient developed a rash, beginning on the face. The patient remained in self-isolation for a further 10 days and sought medical care for the relief of symptoms. The patient was admitted to a referral hospital on 23 May.
Monkeypox causes a rash and pus-filled blisters to grow on the body and can be contracted via bedsheets, touching or clothing. While the disease is disturbing to see, it is usually not fatal. Follow-up is being undertaken for the contacts of the two cases for 21 days after their last exposure. No close contacts have travelled outside the United Kingdom following exposure.
While a vaccine was approved for the disease in 2019, and the traditional smallpox vaccine provides cross-protection for Monkeypox, these vaccines are not widely available. There is little immunity to the infection in those exposed as the endemic disease is geographically limited to West and Central Africa.